Idorsia reports positive results from Phase II programme of insomnia drug

Swiss biopharmaceutical firm Idorsia has reported positive results from a Phase II programme of ACT-541468 to treat patients suffering from insomnia.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news